Cargando…

Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases

PURPOSE: Interleukin-6 (IL-6) production and signalling are increased in the inflamed mucosa in inflammatory bowel diseases (IBD). As published serum levels of IL-6 and its soluble receptors sIL-6R and sgp130 in IBD are from small cohorts and partly contradictory, we systematically evaluated IL-6, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikolaus, Susanna, Waetzig, Georg H., Butzin, Sven, Ziolkiewicz, Monika, Al-Massad, Natalie, Thieme, Florian, Lövgren, Ulf, Rasmussen, Birgitte B., Reinheimer, Torsten M., Seegert, Dirk, Rosenstiel, Philip, Szymczak, Silke, Schreiber, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002455/
https://www.ncbi.nlm.nih.gov/pubmed/29748708
http://dx.doi.org/10.1007/s00384-018-3069-8
_version_ 1783332209027973120
author Nikolaus, Susanna
Waetzig, Georg H.
Butzin, Sven
Ziolkiewicz, Monika
Al-Massad, Natalie
Thieme, Florian
Lövgren, Ulf
Rasmussen, Birgitte B.
Reinheimer, Torsten M.
Seegert, Dirk
Rosenstiel, Philip
Szymczak, Silke
Schreiber, Stefan
author_facet Nikolaus, Susanna
Waetzig, Georg H.
Butzin, Sven
Ziolkiewicz, Monika
Al-Massad, Natalie
Thieme, Florian
Lövgren, Ulf
Rasmussen, Birgitte B.
Reinheimer, Torsten M.
Seegert, Dirk
Rosenstiel, Philip
Szymczak, Silke
Schreiber, Stefan
author_sort Nikolaus, Susanna
collection PubMed
description PURPOSE: Interleukin-6 (IL-6) production and signalling are increased in the inflamed mucosa in inflammatory bowel diseases (IBD). As published serum levels of IL-6 and its soluble receptors sIL-6R and sgp130 in IBD are from small cohorts and partly contradictory, we systematically evaluated IL-6, sIL-6R and sgp130 levels as markers of disease activity in Crohn’s disease (CD) and ulcerative colitis (UC). METHODS: Consecutive adult outpatients with confirmed CD or UC were included, and their disease activity and medication were monitored. Serum from 212 CD patients (815 measurements) and 166 UC patients (514 measurements) was analysed, and 100 age-matched healthy blood donors were used as controls. RESULTS: IL-6 serum levels were significantly elevated in active versus inactive CD and UC, also compared with healthy controls. However, only a fraction of IBD patients showed increased serum IL-6. IL-6 levels ranged up to 32.7 ng/mL in active CD (> 5000-fold higher than in controls), but also up to 6.9 ng/mL in inactive CD. Increases in active UC (up to 195 pg/mL) and inactive UC (up to 27 pg/mL) were less pronounced. Associations between IL-6 serum levels and C-reactive protein concentrations as well as leukocyte and thrombocyte counts were observed. Median sIL-6R and sgp130 levels were only increased by up to 15%, which was considered of no diagnostic significance. CONCLUSIONS: Only a minority of IBD patients shows elevated IL-6 serum levels. However, in these patients, IL-6 is strongly associated with disease activity. Its soluble receptors sIL-6R and sgp130 do not appear useful as biomarkers in IBD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00384-018-3069-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6002455
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-60024552018-06-29 Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases Nikolaus, Susanna Waetzig, Georg H. Butzin, Sven Ziolkiewicz, Monika Al-Massad, Natalie Thieme, Florian Lövgren, Ulf Rasmussen, Birgitte B. Reinheimer, Torsten M. Seegert, Dirk Rosenstiel, Philip Szymczak, Silke Schreiber, Stefan Int J Colorectal Dis Original Article PURPOSE: Interleukin-6 (IL-6) production and signalling are increased in the inflamed mucosa in inflammatory bowel diseases (IBD). As published serum levels of IL-6 and its soluble receptors sIL-6R and sgp130 in IBD are from small cohorts and partly contradictory, we systematically evaluated IL-6, sIL-6R and sgp130 levels as markers of disease activity in Crohn’s disease (CD) and ulcerative colitis (UC). METHODS: Consecutive adult outpatients with confirmed CD or UC were included, and their disease activity and medication were monitored. Serum from 212 CD patients (815 measurements) and 166 UC patients (514 measurements) was analysed, and 100 age-matched healthy blood donors were used as controls. RESULTS: IL-6 serum levels were significantly elevated in active versus inactive CD and UC, also compared with healthy controls. However, only a fraction of IBD patients showed increased serum IL-6. IL-6 levels ranged up to 32.7 ng/mL in active CD (> 5000-fold higher than in controls), but also up to 6.9 ng/mL in inactive CD. Increases in active UC (up to 195 pg/mL) and inactive UC (up to 27 pg/mL) were less pronounced. Associations between IL-6 serum levels and C-reactive protein concentrations as well as leukocyte and thrombocyte counts were observed. Median sIL-6R and sgp130 levels were only increased by up to 15%, which was considered of no diagnostic significance. CONCLUSIONS: Only a minority of IBD patients shows elevated IL-6 serum levels. However, in these patients, IL-6 is strongly associated with disease activity. Its soluble receptors sIL-6R and sgp130 do not appear useful as biomarkers in IBD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00384-018-3069-8) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-05-11 2018 /pmc/articles/PMC6002455/ /pubmed/29748708 http://dx.doi.org/10.1007/s00384-018-3069-8 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Nikolaus, Susanna
Waetzig, Georg H.
Butzin, Sven
Ziolkiewicz, Monika
Al-Massad, Natalie
Thieme, Florian
Lövgren, Ulf
Rasmussen, Birgitte B.
Reinheimer, Torsten M.
Seegert, Dirk
Rosenstiel, Philip
Szymczak, Silke
Schreiber, Stefan
Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases
title Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases
title_full Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases
title_fullStr Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases
title_full_unstemmed Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases
title_short Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases
title_sort evaluation of interleukin-6 and its soluble receptor components sil-6r and sgp130 as markers of inflammation in inflammatory bowel diseases
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002455/
https://www.ncbi.nlm.nih.gov/pubmed/29748708
http://dx.doi.org/10.1007/s00384-018-3069-8
work_keys_str_mv AT nikolaussusanna evaluationofinterleukin6anditssolublereceptorcomponentssil6randsgp130asmarkersofinflammationininflammatoryboweldiseases
AT waetziggeorgh evaluationofinterleukin6anditssolublereceptorcomponentssil6randsgp130asmarkersofinflammationininflammatoryboweldiseases
AT butzinsven evaluationofinterleukin6anditssolublereceptorcomponentssil6randsgp130asmarkersofinflammationininflammatoryboweldiseases
AT ziolkiewiczmonika evaluationofinterleukin6anditssolublereceptorcomponentssil6randsgp130asmarkersofinflammationininflammatoryboweldiseases
AT almassadnatalie evaluationofinterleukin6anditssolublereceptorcomponentssil6randsgp130asmarkersofinflammationininflammatoryboweldiseases
AT thiemeflorian evaluationofinterleukin6anditssolublereceptorcomponentssil6randsgp130asmarkersofinflammationininflammatoryboweldiseases
AT lovgrenulf evaluationofinterleukin6anditssolublereceptorcomponentssil6randsgp130asmarkersofinflammationininflammatoryboweldiseases
AT rasmussenbirgitteb evaluationofinterleukin6anditssolublereceptorcomponentssil6randsgp130asmarkersofinflammationininflammatoryboweldiseases
AT reinheimertorstenm evaluationofinterleukin6anditssolublereceptorcomponentssil6randsgp130asmarkersofinflammationininflammatoryboweldiseases
AT seegertdirk evaluationofinterleukin6anditssolublereceptorcomponentssil6randsgp130asmarkersofinflammationininflammatoryboweldiseases
AT rosenstielphilip evaluationofinterleukin6anditssolublereceptorcomponentssil6randsgp130asmarkersofinflammationininflammatoryboweldiseases
AT szymczaksilke evaluationofinterleukin6anditssolublereceptorcomponentssil6randsgp130asmarkersofinflammationininflammatoryboweldiseases
AT schreiberstefan evaluationofinterleukin6anditssolublereceptorcomponentssil6randsgp130asmarkersofinflammationininflammatoryboweldiseases